Multiple Sclerosis
Literature Review
Advancing health equity in neurology is essential to patient care
The final plenary session at the ANA annual conference offered insights into the underlying causes of health care disparities within neurology and...
Conference Coverage
Even mild MS relapses may signal faster disability accumulation
Nondisabling relapses “should be considered in decisions to initiate or escalate treatment, including with high-efficacy therapies.”
Conference Coverage
Stem cell therapy strikes out in progressive MS
A retrospective study suggests no advantage of AHSCT over disease-modifying therapy in progressive MS.
Conference Coverage
More evidence for EBV’s role in MS
Genetic sequencing of T-cell responses suggests the possibility of an ongoing immune response.
Conference Coverage
New research confirms recommendations on COVID-19 boosters in MS
“Even MS patients whose B cells were depleted from circulation with ocrelizumab can mount immune responses to COVID-19 vaccines.”
Conference Coverage
GFAP may complement NfL as MS biomarker
GFAP is linked to progression while NfL is linked to inflammation.
Conference Coverage
Can MS be stopped early in its tracks?
Dimethyl fumarate reduced the risk of a first acute or progressive event related to CNS demyelination by more than 80%, compared with placebo.
Conference Coverage
Is MRI a viable alternative to lumbar puncture for MS diagnosis?
In many cases, the central vein sign on MRI could obviate the need for a spinal tap.
Conference Coverage
NfL levels might presage MS disability
A spike occurred about a year before clinical worsening.
Conference Coverage
A better way to predict fall risk in patients with MS?
“Instead of looking at reduced maximum muscle strength, perhaps we should start looking at reduced rate of force development when trying to...
Conference Coverage
‘Reassuring data’ for two MS meds in pregnancy
Preterm birth, spontaneous abortions, and major congenital anomalies were rare with anti-CD20 drugs ocrelizumab or natalizumab.